We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.74B
AUM Growth
+$71.7M
Cap. Flow
+$132M
Cap. Flow %
7.63%
Top 10 Hldgs %
59.59%
Holding
81
New
17
Increased
17
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$85.8M
2
VERA icon
Vera Therapeutics
VERA
+$45.3M
3
BIIB icon
Biogen
BIIB
+$33.5M
4
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.1M
2
LLY icon
Eli Lilly
LLY
+$33.7M
3
MRUS
Merus
MRUS
+$27.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$352M 20.29%
3,100,560
– –
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$223M 12.83%
1,952,441
– –
JBIO
3
Jade Biosciences
JBIO
$1.22B
$85.8M 4.95%
+107,391
New +$85.8M
YMAB
4
DELISTED
Y-mAbs Therapeutics
YMAB
$74.2M 4.27%
2,194,278
– –
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$68.7M 3.96%
521,923
– –
AZN icon
6
AstraZeneca
AZN
$263B
$57.5M 3.31%
479,816
-38,050
-7% -$4.17M
OEF icon
7
PUT
iShares S&P 100 ETF
OEF
$19.8B
$53.2M 3.07%
+325,000
New +$61.7M
BOLT icon
8
Bolt Biotherapeutics
BOLT
$7.36M
$42.6M 2.45%
137,722
– –
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$38.8M 2.23%
216,085
+1,031
+0.5% +$196K
VERA icon
10
Vera Therapeutics
VERA
$2.54B
$38.6M 2.23%
+2,914,776
New +$45.3M
BIIB icon
11
Biogen
BIIB
$29.9B
$38.3M 2.21%
+110,600
New +$33.5M
INZY
12
DELISTED
Inozyme Pharma
INZY
$34.6M 1.99%
2,028,308
– –
GRTX
13
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$30.3M 1.75%
3,083,712
– –
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$29.3M 1.69%
233,638
+55,100
+31% +$6.95M
ALGN icon
15
Align Technology
ALGN
$12B
$28.8M 1.66%
47,093
+1,593
+4% +$943K
PTCT icon
16
PTC Therapeutics
PTCT
$6.37B
$24.6M 1.42%
581,940
+115,100
+25% +$4.93M
INSM icon
17
Insmed
INSM
$23.2B
$24M 1.38%
844,169
+225,219
+36% +$6.68M
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.66B
$23.2M 1.34%
+298,500
New +$22.6M
ARKG icon
19
PUT
ARK Genomic Revolution ETF
ARKG
$1.51B
$23.1M 1.33%
+250,000
New +$21.3M
HRTX icon
20
Heron Therapeutics
HRTX
$86.3M
$22.8M 1.31%
+1,467,675
New +$23.3M
CMPI
21
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$21.5M 1.24%
3,606,707
– –
NXTC icon
22
NextCure
NXTC
$17.3M
$21.5M 1.24%
222,655
– –
PTGX icon
23
Protagonist Therapeutics
PTGX
$8.75B
$20.2M 1.16%
449,082
-205,818
-31% -$6.79M
NBIX icon
24
Neurocrine Biosciences
NBIX
$17.7B
$19.8M 1.14%
+203,200
New +$19.5M
EXEL icon
25
Exelixis
EXEL
$13.9B
$19.7M 1.13%
1,079,681
+240,500
+29% +$5.61M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2021 Portfolio in Review

As of Q2 2021, Sofinnova Investments held 81 positions worth $1.74B, up 4.3% from $1.66B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $132M of net new capital in Q2 2021, opening 17 new positions and adding to 17 existing holdings. Its largest new stake was Jade Biosciences: 107,391 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $17.9M trimmed.

  • Sofinnova Investments's largest Q2 2021 buy was Jade Biosciences: 107,391 shares worth $85.8M.
  • Sofinnova Investments added most to Insulet in Q2 2021, an estimated $13.9M increase.
  • Sofinnova Investments's biggest Q2 2021 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $17.9M.
  • Sofinnova Investments fully exited Jazz Pharmaceuticals in Q2 2021, selling an estimated $42.1M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.74B portfolio in Q2 2021.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q2 2021.
  • Sofinnova Investments's portfolio value rose 4.3% quarter-over-quarter to $1.74B.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.